Healthcare can be complicated.
Your cardiology news shouldn’t be.

Join thousands of cardiology leaders today.

Pharmaceuticals December 9, 2024

Tirzepatide Triumphant Over Semaglutide December 9, 2024

Topline results from the SURMOUNT-5 trial found Eli Lilly’s tirzepatide led to far greater weight loss than Novo Nordisk’s semaglutide, giving Lilly a boost in the race to become America’s go-to GLP-1.  Over SURMOUNT-5’s 72 week duration, 751 participants across the U.S. and Puerto Rico were randomized to receive the maximum tolerated dose of tirzepatide […]

Pharmaceuticals December 5, 2024

MariTide’s Weight Loss Milestone December 5, 2024

The red hot weight loss segment just got even hotter, as the Phase 2 trial of Amgen’s maridebart cafraglutide (MariTide) yielded exceptional body mass reductions among people with obesity and T2D, propelling the pharma giant closer to FDA approval. Building on this earlier success, Amgen’s new Phase 2 trial lasted 52 weeks and enrolled patients […]

Pharmaceuticals December 2, 2024

Winrevair’s Big PAH Win December 2, 2024

Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. The ZENITH trial randomized 172 patients to either receive Winrevair and background PAH therapy, or placebo and PAH therapy. […]

Cholesterol Reduction November 25, 2024

Muvalaplin Aces Phase 2 Lp(a) Test November 25, 2024

Impressive results from the Phase 2 KRAKEN trial presented at the AHA 2024 Scientific Sessions showed that Eli Lilly’s muvalaplin greatly reduces Lp(a) blood levels, adding an attractive oral option to its Lp(a) pipeline. By the study’s 12-week endpoint, patients experienced significant reductions in blood Lp(a) when taking oral muvalaplin across three different doses, compared […]

Cardiology November 21, 2024

Ablation or Antiarrhythmics for Ventricular Tachycardia? November 21, 2024

Late-breaking results from the VANISH2 trial presented at AHA 2024 showed that catheter ablation might be a better first-line treatment than antiarrhythmic drugs for ventricular tachycardia patients with ischemic cardiomyopathy. To address this uncertainty, the VANISH2 trial recruited 416 patients with clinically significant VT, ischemic cardiomyopathy, previous MI, and an ICD, randomizing them to receive […]

Pharmaceuticals November 18, 2024

Tirzepatide’s Prediabetes Triumph November 18, 2024

Eli Lilly’s GLP-1 tirzepatide has triumphed yet again, as the full SURMOUNT-1 trial showed that the drug kept nearly 99% of prediabetic patients diabetes-free over 3 years, while improving cardiometabolic metrics. In the final results from the three-year SURMOUNT-1 trial, tirzepatide lowered the risk of progression to Type 2 diabetes by 94% versus placebo in […]

Surgeries & Interventions November 14, 2024

Forgotten IVC Filters Aren’t SAFE November 14, 2024

Troubling results from the SAFE-IVC study revealed that just one in six patients gets their inferior vena cava filters removed, despite clear guidelines calling for IVC filter removal as early as possible. Out of SAFE-IVC’s roughly 270k Medicare beneficiaries, only 15% had their IVC filters retrieved within 1.2 years of insertion. Patients who didn’t have […]

Surgeries & Interventions November 11, 2024

LimFlow Limits Limb-Threatening Ischemia November 11, 2024

Late-breaking second year results from the PROMISE II trial showed that the LimFlow system achieved strong outcomes for avoiding amputations and promoting limb salvage among “no-option” patients with chronic limb-threatening ischemia (CLTI).  LimFlow remained effective at two years, with a 65% limb salvage rate that was just 4% below the PROMISE II trial’s one year […]

Atrial Fibrillation November 7, 2024

Boston Scientific Bolsters AFib Mapping with Cortex Acquisition November 7, 2024

Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. for an undisclosed sum. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases. […]

Surgeries & Interventions November 4, 2024

TCT 2024’s Top TAVR Studies November 4, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Out of all these TAVR studies, the four that could have the greatest clinical impact focused on interventional timing and the risk of comorbidities and procedural complications. The EARLY […]

Cardiology October 31, 2024

The 40 Best Cardiology Newsletters, Websites, and Influencers to Follow in 2024 October 31, 2024

We’re dedicating today’s top story to the people and publications that we rely on to find the most interesting cardiology stories from across the web. Assuming that you already subscribe to Cardiac Wire, these are the 40 other newsletters, websites, and social media stars to follow if you want to keep up with the latest […]

Cardiovascular Disease October 28, 2024

America’s Growing CVD Problem October 28, 2024

It’s well known that heart disease is the U.S.’s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. The Takeaway These truly frightening statistics suggest that the […]

Cardiology October 24, 2024

The State of Cardiology Employment October 24, 2024

MedAxiom released its 12th annual Cardiovascular Provider Compensation and Production Report, providing an in-depth look at the current state of working in cardiology. The massive 60-page report (n=5,663 providers, 202 programs, 2023 data) outlined four notable employment trends… Rising PE Ownership – Nearly 50% of surveyed private practice groups were also part of a private […]

Pharmaceuticals October 21, 2024

Exploring Semaglutide’s Cardiovascular Impact October 21, 2024

JACC took a deep dive into semaglutide’s cardiovascular impact, publishing six analyses of three separate trials that delivered new insights into the drug’s heart benefits, while raising even more questions about how it works. One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight […]

Atrial Fibrillation October 17, 2024

InCarda Gets Mixed Results in AFib Inhaler Trial October 17, 2024

AFib inhalers took a small step closer to becoming a reality after InCarda Therapeutics’ Phase 3 RESTORE-1 trial showed that its FlecIH-103 inhaled flecainide formulation can rapidly convert paroxysmal AFib to normal sinus rhythm. However, challenges with the study suggest that InCarda has more work to do in order to achieve this reality. The new […]

Cholesterol Reduction October 10, 2024

AstraZeneca Adds Lp(a) Candidate with CSPC Licensing Move October 10, 2024

AstraZeneca expanded its cardiovascular pipeline this week, signing an exclusive license agreement for CSPC Pharmaceutical Group’s Lp(a) disruptor candidate, YS2302018. The deal comes with a $100M upfront investment that could reach $1.92B depending on further milestones. CSPC’s YS2302018 addresses a sizable target market, noting that nearly 70% of patients with CVD aren’t meeting guideline-directed LDL-C […]

Heart Failure October 7, 2024

Finerenone’s Early Heart Failure Impact October 7, 2024

The FINEARTS-HF trial already showed that Bayer’s nsMRA finerenone (Kerendia) has the potential to slash mortality and event rates in HFpEF and HFmrEF patients, and new analysis suggests that its impact could be even greater if used earlier. The original FINEARTS-HF trial presented at ESC 2024 saw finerenone drive a 16% reduction in cardiovascular death […]

Heart Failure October 3, 2024

EMBARK-HFpEF Trial Flexes Mavacamten’s HF Potential October 3, 2024

A new HFpEF treatment might be on the horizon, after results from the EMBARK-HFpEF trial showed that BMS’ hypertrophic cardiomyopathy treatment, mavacamten (Camzyos), safely improved key HFpEF symptoms and biomarkers. To test mavacamten’s HFpEF potential, the open-label Phase 2a EMBARK-HFpEF trial treated 30 HFpEF patients with mavacamten (avg age 76, NYHA Class II & III, […]

Preventive Cardiology September 30, 2024

Cancer’s CVD Risks and SGLT2is’ Preventative Potential September 30, 2024

Better treatments have led to improved cancer survival rates, but new research reveals increased cardiovascular complications in survivors. However, another new study offers hope, suggesting that heart medications like SGLT2 inhibitors may help prevent cancer-related heart disease. A new Cancer Journal study showed that older cancer survivors have far higher rates of cardiovascular events than […]

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!